MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Siremadlin

CAS No. : 1448867-41-1

MCE 国际站：Siremadlin

产品活性：Siremadlin (NVP-HDM201) 是口服有效的选择性 p53-MDM2 抑制剂。

研究领域：Apoptosis | Metabolic Enzyme/Protease

作用靶点：MDM-2/p53 | E1/E2/E3 Enzyme

In Vitro: Siremadlin (NVP-HDM201) disrupts both human and murine TP53- MDM2 interactions, with nanomolar cellular IC₅₀ values, blocking TP53 degradation.

In Vivo: Siremadlin (NVP-HDM201) is an imidazolopyrrolidinone analogue, showing a very advantageous in vivo profile. NVP-HDM201 has recently entered Phase 1 clinical trials in cancer patients. Constitutive PB mutagenesis in Arf^−/− mice provides a collection of spontaneous tumors with characterized insertional genetic landscapes. Tumors are allografted in large cohorts of mice to assess the pharmacologic effects of Siremadlin (NVP-HDM201). Sixteen out of 21 allograft models are sensitive to Siremadlin (NVP-HDM201) but ultimately relapse under treatment. A comparison of tumors with acquired resistance to Siremadlin (NVP-HDM201) and untreated tumors identified 87 genes that are differentially and significantly targeted by the PB transposon. Siremadlin (NVP-HDM201) administered either daily at a low dose or once at a high dose revealed a differentiated engagement of the p53 molecular response. In contrast to the daily low dose treatment regimen, the single high dose Siremadlin (NVP-HDM201) regimen results in a rapid and dramatic induction of p53-dependent PUMA expression and apoptosis. This is consistent with the finding that a single high dose Siremadlin (NVP-HDM201) treatment, administered orally or intravenously, results in a robust and sustained tumor regression. Overall, both daily and once every 3 weeks dosing regimen shows comparable long term efficacy in preclinical studies. The ongoing clinical trial is currently designed to compare both dosing regimens with regard to efficacy and tolerability.

相关产品：Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Apoptosis Compound Library | Metabolism/Protease Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Oxygen Sensing Compound Library | Ubiquitination Compound Library | Ferroptosis Compound Library | Pyroptosis Compound Library | Orally Active Compound Library | Glutamine Metabolism Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Nutlin-3a | Pifithrin-α hydrobromide | Eprenetapopt | PYR-41 | BI8622 | Ginkgolic Acid | SZL P1-41 | 2-D08 | Amifostine | Pifithrin-µ | RITA | Indole-3-carbinol | NSC232003 | BI8626 | PRT4165 | MI⁻⁷73 | Pifithrin-α, p-Nitro, Cyclic | DKM 2-93 | NSC319726 | Amifostine thiol dihydrochloride | PYZD-4409 | PK11007 | SMIP004 | Solasodine | Inauhzin | SJ-172550 | TZ9

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。